THOUSANDS of patients with HER2-negative breast cancer may find a new lifeline in Enhertu , a drug from AstraZeneca which can slow cancer progression and improve survival by six months in certain cases.
Monday, 6 June 2022
‘Dramatic’ AstraZeneca results offer lifeline for thousands of breast cancer patients
THOUSANDS of patients with HER2-negative breast cancer may find a new lifeline in Enhertu , a drug from AstraZeneca which can slow cancer progression and improve survival by six months in certain cases.
0 comments:
Post a Comment